Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease characterized by recurrent itchy, dry, and inflamed skin lesions, often beginning in childhood and persisting or recurring in adults.
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
FDA approved roflumilast cream 0.3% (Zoryve) for plaque psoriasis in children age 2+, the first once-daily steroid-free topical for that group. A meta-analysis found it improved IGA scores and was well tolerated.
A phase 2 clinical trial published in The Lancet Gastroenterology & Hepatology found that dupilumab significantly improved symptoms and biological markers in patients with eosinophilic gastritis, a rare stomach disease with no approved treatments. The DEGAS study involved 41 patients across 11 U.S. centers.
Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.
Kymera Therapeutics presented Phase 1 data for oral STAT6 degrader KT-621 in healthy Japanese adults, showing ≥98% STAT6 degradation and favorable safety. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected in 2027, and FDA has granted Fast Track designation for both indications.
Apogee Therapeutics will present Phase 2 APEX Part B data for zumilokibart on May 27, 2026. Affinity Asset Advisors increased its stake to 1.23 million shares valued at $93.21 million. The stock rose 86.9% over the past year.
A mouse study identified **TRPV4** as part of the neural feedback system that tells the brain when scratching has been sufficient. The findings suggest broadly blocking TRPV4 may not be the solution for chronic itch.
Zai Lab's Q1 2026 revenue fell 6% to $99.6 million, missing expectations, while EPS beat at -$0.05. The company highlighted Zoci intracranial response data and expects three pivotal trials by year-end 2026.
Animal health markets are projected to expand in 2026, led by animal biotechnology at $34.6 billion to $36.19 billion and continued growth in veterinary antibiotics. Demand is being driven by companion animal care, livestock health, biologics R&D, and tighter oversight of antibiotic use.
Arcutis is in focus after new Phase 3 extension data for Zoryve cream 0.05% in young children with atopic dermatitis and ahead of its Feb. 25 Q4 results. Investors are also watching recent FDA actions and pipeline updates for additional pediatric and dermatology indications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07765888 |
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema |
NOT_YET_RECRUITING | PHASE3 |
| NCT07762833 |
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07754968 |
Use of Bifidobacterium Bifidum in Formula-Fed Infants With Colic, With or Without Atopic Dermatitis |
RECRUITING | NA |
| NCT07754786 |
A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07748169 |
An Observational Study of Patients With Dermatologic Disease |
RECRUITING | |
| NCT07746817 |
A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07746427 |
Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis |
RECRUITING | NA |
| NCT07741838 |
Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp) |
NOT_YET_RECRUITING | |
| NCT07734415 |
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07713186 |
Azithromycin in Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE4 |
